1Department of Neurosurgery, Yonsei University Wonju College of Medicine, Wonju.
2Department of Neurosurgery, Dong-A University College of Medicine, Busan; and.
J Neurosurg. 2018 Dec 1;129(Suppl1):47-54. doi: 10.3171/2018.7.GKS181589.
OBJECTIVEThis study investigated long-term follow-up data on the combined pituitary function test (CPFT) in patients who had undergone transsphenoidal surgery (TSS) for nonfunctioning pituitary adenoma (NFPA) to determine the clinical parameters indicative of hypopituitarism following postoperative Gamma Knife surgery (GKS).METHODSBetween 2001 and 2015, a total of 971 NFPA patients underwent TSS, and 76 of them (7.8%) underwent postoperative GKS. All 76 patients were evaluated with a CPFT before and after GKS. The hormonal states were analyzed based on the following parameters: relevant factors before GKS (age, sex, extent of resection, pre-GKS hormonal states, time interval between TSS and GKS), GKS-related factors (tumor volume; radiation dose to tumor, pituitary stalk, and normal gland; distance between tumor and stalk), and clinical outcomes (tumor control rate, changes in hormonal states, need for hormone-related medication due to hormonal changes).RESULTSOf the 971 NFPA patients, 797 had gross-total resection (GTR) and 174 had subtotal resection (STR). Twenty-five GTR patients (3.1%) and 51 STR patients (29.3%) underwent GKS. The average follow-up period after GKS was 53.5 ± 35.5 months, and the tumor control rate was 96%. Of the 76 patients who underwent GKS, 23 were excluded due to pre-GKS panhypopituitarism (22) or loss to follow-up (1). Hypopituitarism developed in 13 (24.5%) of the remaining 53 patients after GKS. A higher incidence of post-GKS hypopituitarism occurred in the patients with normal pre-GKS hormonal states (41.7%, 10/24) than in the patients with abnormal pre-GKS hormonal states (10.3%, 3/29; p = 0.024). Target tumor volume (4.7 ± 3.9 cm3), distance between tumor and pituitary stalk (2.0 ± 2.2 mm), stalk dose (cutoffs: mean dose 7.56 Gy, maximal dose 12.3 Gy), and normal gland dose (cutoffs: maximal dose 13.9 Gy, minimal dose 5.25 Gy) were factors predictive of post-GKS hypopituitarism (p < 0.05).CONCLUSIONSThis study analyzed the long-term follow-up CPFT data on hormonal changes in NFPA patients who underwent GKS after TSS. The authors propose a cutoff value for the radiation dose to the pituitary stalk and normal gland for the prevention of post-GKS hypopituitarism.
本研究旨在探讨经蝶窦手术(TSS)治疗无功能性垂体腺瘤(NFPA)患者的长期随访联合垂体功能检查(CPFT)结果,以确定伽玛刀手术后(GKS)发生垂体功能减退的临床参数。
2001 年至 2015 年间,共有 971 例 NFPA 患者接受了 TSS,其中 76 例(7.8%)患者术后接受了 GKS。76 例患者均在 GKS 前后接受 CPFT 检查。根据以下参数分析激素状态:GKS 前的相关因素(年龄、性别、切除范围、术前激素状态、TSS 与 GKS 之间的时间间隔)、GKS 相关因素(肿瘤体积;肿瘤、垂体柄和正常腺体的辐射剂量;肿瘤与垂体柄之间的距离)和临床结果(肿瘤控制率、激素状态变化、因激素变化而需要激素相关药物治疗的情况)。
971 例 NFPA 患者中,797 例为全切除(GTR),174 例为次全切除(STR)。25 例 GTR 患者(3.1%)和 51 例 STR 患者(29.3%)接受了 GKS。GKS 后平均随访时间为 53.5±35.5 个月,肿瘤控制率为 96%。在接受 GKS 的 76 例患者中,有 23 例因术前全垂体功能减退(22 例)或失访(1 例)而被排除在外。在其余 53 例患者中,有 13 例(24.5%)在 GKS 后出现垂体功能减退。在术前激素状态正常(41.7%,10/24)的患者中,GKS 后发生垂体功能减退的发生率高于术前激素状态异常(10.3%,3/29;p=0.024)。靶肿瘤体积(4.7±3.9cm3)、肿瘤与垂体柄之间的距离(2.0±2.2mm)、垂体柄剂量(阈值:平均剂量 7.56Gy,最大剂量 12.3Gy)和正常腺体剂量(阈值:最大剂量 13.9Gy,最小剂量 5.25Gy)是预测 GKS 后垂体功能减退的因素(p<0.05)。
本研究分析了 TSS 后接受 GKS 治疗的 NFPA 患者长期随访的 CPFT 激素变化数据。作者提出了垂体柄和正常腺体辐射剂量的阈值,以预防 GKS 后发生垂体功能减退。